Marstacimab
Based on 1 Customer Validation
Marstacimab (PF-06741086) is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody. Marstacimab can be used for the research of hemophilia.
For research use only. We do not sell to patients.
- Purity : 96.27%
- CAS No.: 1985638-39-8
- Molecular Weight:145.98 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Isotype
Human IgG1 lambda2
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
TFPI
In Vitro
Marstacimab (20, 50 and 100 nmol/L) decreases rotational thromboelastometry (ROTEM) corn trypsin (CT) of the whole blood that obtained from haemophilia participants[1]. Marstacimab (16 μg/mL) decreases the lag time and increases thrombin generation of human nonhemophilic plateletpoor plasma samples in vitro[2]. Marstacimab (16 μg/mL) increases the peak thrombin in both hemophilia A and hemophilia B plasma samples in vitro[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Acute bleeding hemophilia A mouse models[2]
-
Dosage:0.5 mg/kg
-
Administration:Intravenous injection, 0.5 mg/kg, once, before tail clip
-
Result:Showed no effect on the blood loss compared with control mice, but significantly reduced the blood loss with the combination of aPCC 200 U/kg.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 lambda2
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow Cytometry analysis of Hela cells labelling TFPI (red) with Marstacimab (anti-TFPI) (HY-P99725). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 lambda2 (HY-P990096). Black-Unlabelled control, cells without incubation with primary antibody.
Chemical Information
-
CAS No. 1985638-39-8
-
Appearance Liquid
-
Molecular Weight 145.98 kDa
-
Color Colorless to light yellow
-
SMILES
[Marstacimab]
-
Synonyms
PF-06741086
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (259 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Patel-Hett S, et al. Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas. Haemophilia. 2019 Sep;25(5):797-806. [Content Brief]
[2]. Pittman DD, et al. Hemostatic efficacy of marstacimab alone or in combination with bypassing agents in hemophilia plasmas and a mouse bleeding model. Res Pract Thromb Haemost. 2022 Mar 16;6(2):e12679. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Marstacimab Related Classifications
HY-P99725 Related Classifications
Powered by Bioz